NEJM Study Highlights Resmetirom's Efficacy in NASH

Investigators from the ongoing MAESTRO-NASH trial provided more evidence that resmetirom may be a viable option in a disease state currently without any approved treatments.

Related Keywords

Texas ,United States ,San Antonio ,Stephen Harrison ,Summit Clinical Research ,Pinnacle Clinical Research ,Madrigal Pharmaceuticals ,New England Journal ,European Association ,Liver Congress ,Closer Look ,Nonalcoholic Fatty Liver Disease ,Afld Non Alcoholic Fatty Liver Disease ,Non Alcoholic Fatty Liver Disease Nafld ,Biliary Disease ,Allbladder Disease ,Metabolic Syndrome ,Liver Fibrosis ,Liver ,Lipids ,Ipid Management ,Fatty Liver ,Teatorrhoeic Hepatosis ,Teatosis Hepatis ,Liver Disease ,Hepatic Impairment ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,